Top Durham, NC Biotech Companies (39)
Flatiron Health is a healthtech company dedicated to helping cancer centers thrive and deliver better care for patients today and tomorrow. Through clinical and data science, we translate patient experiences into real-world evidence to improve treatment, inform policy, and advance research. Cancer is smart. Together, we can be smarter. Flatiron Health is an independent affiliate of the Roche Group.
Our purpose ensures that patients remain at the center of all we do. We live our purpose by sourcing the best science in the world; partnering with others in the healthcare system to improve access to our medicines; using digital technologies to enhance our drug discovery and development, as well as patient outcomes; and leading the conversation to advocate for pro-innovation/pro-patient policies.
New reverse osmosis membranes are what the industry has been waiting for. Reverse osmosis has been proven to be the most efficient way to purify water. However, this process has also proven to be more expensive than what it could be. We will bring innovation to desalination by introducing these new membranes that will knock out biofouling and ultimately be more cost-efficient.
Aerami Therapeutics is developing a new generation of inhaled therapies for the treatment of severe respiratory and chronic diseases. Our platform is designed to overcome the limitations of injectable, oral, and other inhaled formulation technologies for managing severe respiratory and chronic diseases. Ultimately, our aim is to improve treatment efficacy and improve patient lives. To learn more, visit: https://aerami.com/
Avazyme, Inc. a contract research solution provider, offering field and laboratory testing, product development, and expert consulting services to the agriculture and food industries. Avazyme’s comprehensive services include food safety analyses for contaminants, pathogens, allergens, food quality and nutrition analysis, genetic trait testing, product safety, FDA Menu Labeling, pesticide residues, mycotoxin analysis, specialized studies for regulatory submission data packages, and a full spectrum of testing for product safety and product quality related to Industrial Hemp. Avazyme provides fast and reliable answers to ensure product safety and high product quality for consumable food, feed, cosmetics, nutraceutical Avazyme also offers comprehensive laboratory and "in-brewery" services to craft breweries and local hops growers and maltsters. Most recently, Volker and his Avazyme team have been a strong supporter and testing partner for the fast-emerging Industrial Hemp Industry in North Carolina and the entire East Coast
AgBiome discovers and develops innovative biological and trait products for crop protection.
Mendel is the technology platform hub for Koch Biological Solutions, a global leader in delivering targeted, science-based biological products to improve crop productivity. In 2019, KBIO became part of Plant Response, Inc.
KBI Biopharma is an award-winning biopharmaceutical contract services organization providing fully-integrated, accelerated drug development and biomanufacturing services to pharmaceutical and biotechnology companies globally. With each of our 500+ client partners, we have worked closely to personalize and rapidly accelerate their drug development programs. Built upon a foundation of world-class analytical capabilities, we deliver efficient process development and clinical and commercial cGMP manufacturing services for mammalian, microbial, and cell therapy programs. KBI is proud to be a JSR Life Sciences Company.
Rewriting the next 100 years of farming
We are a biotech company with a fierce commitment to the patients and communities we serve. Period. We are a company dedicated to recoding science so we can help rewrite the stories of those living with severe genetic diseases and cancer. We live by our non-negotiables: authenticity, courage, humility, caring and transparency. Every day, in every interaction.
Brii Biosciences (Brii Bio) is a company committed to serving patients’ needs and improving public health in China. Founded in early 2018, the company focuses on accelerating innovation and optimizing access to the latest medicines for Chinese patients. Brii Bio helps global partners drive growth and improve return on investment through better understanding of Chinese healthcare systems and access to the world’s second largest pharmaceutical market. The company’s focus is treatments for chronic illnesses with significant burdens, including infectious diseases, liver and lung diseases, and other illnesses. The company is headquartered in the People’s Republic of China and the United States, with offices in Shanghai, Beijing, San Francisco, and Durham, North Carolina.
Pioneering Diagnostics A world leader in the field of in vitro diagnostics for over 55 years, bioMérieux is present in 44 countries and serves more than 160 countries with the support of a large network of distributors. In 2020, revenues reached €3.1 billion, with over 90% of sales outside of France. bioMérieux provides diagnostic solutions (systems, reagents, software, services) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are mainly used for diagnosing infectious diseases. They are also used for detecting microorganisms in agri-food, pharmaceutical and cosmetic products. bioMérieux is listed on the Euronext Paris stock market.
StrideBio is a product-driven, fully integrated gene therapy company focused on creating and developing innovative genetic medicines with life-changing or curative potential for patients with devastating conditions, including monogenic rare disease and beyond. We leverage our proprietary structure-inspired adeno-associated virus (AAV) vector engineering platform to create unique and differentiated vectors that improve upon naturally occurring AAV serotypes to overcome current limitations of first-generation gene therapies. Improved characteristics of StrideBio’s AAV vectors include evasion of pre-existing neutralizing antibodies, tissue targeting and de-targeting, enhanced potency, and manufacturability at scale. Combined with our gene construct design expertise and in-house manufacturing capabilities, StrideBio is positioned to generate best-in-class genetic medicines that allow more patients to benefit with maximum efficiency. StrideBio is based in a state-of-the-art 24,000-square-foot facility in Research Triangle Park, N.C, which houses our offices, research labs and in-house AAV manufacturing facilities.
Transforming lives through advancements in biomaterials.
Grant Engine is regularly identified as the leading platform for securing non-dilutive funding. We work directly with you to develop the right, best story to secure funding for your products. We write the grant with your essential inputs. As a team of scientists and entrepreneurs, Grant Engine understands what it takes to build a differentiated product to improve the standard of care to address an unmet clinical need. With win rates at 2 to 4x better than the national average, a proven team, and a focus on advancing differentiated products that improve the standard of care, we partner with select companies who want to save lives.
Altis has developed a patent-pending stem cell technology recreating the human intestinal epithelium for compound screening and microbiome research. The product is called RepliGut. It will allow drugs to be tested on an in vitro platform that more closely mimics native human biology. Our goal is to enable pharmaceutical companies to identify effective compounds earlier, before clinical trials; to reduce animal testing; and to make the drug development process faster, cheaper, and safer. Currently, 88% of drugs fail during clinical trials. Part of the reason is that during preclinical studies, drugs are tested using tumor cells and animals. These cannot accurately indicate the way that pharmaceuticals will behave in the human body. The current market lacks a viable method for testing drugs, prior to human testing, and RepliGut will more accurately reflect drug behavior in humans.
Isolere is re-imagining how complex biologics can be manufactured more efficiently. To achieve this, we have combined two phenomena highly evolved by nature -- specific affinity binding and liquid-liquid phase separation. Our team of passionate and talented scientists are working to bring an adeno-associated virus (AAV) manufacturing technology--IsoTag AAV--to market. IsoTag promises to address today's major AAV production bottlenecks. Our mission is to revolutionize the bioprocessing industry, accelerate research and development timelines, and make life-changing cell and gene therapies more globally accessible.
As the industry’s best-in-class, complete real world evidence (RWE) solution, Target RWE is a distinctly collaborative enterprise that unifies real world data (RWD) sets and advanced RWE analytics in an integrated community, shifting the paradigm in healthcare for how decisions are made to improve lives. Target RWE sources unique, connected data sets across multiple therapeutic areas representing granular data from diverse patients in academic and community settings. Our rigorous, interactive, and advanced RWE analytics extract deep insights from RWD to answer important questions in healthcare. Target RWE brings together the brightest minds in healthcare through an unmatched community of key opinion leaders, patients, and healthcare stakeholders in a collaborative and dynamic model. Learn more about Target RWE: www.targetrwe.com
Tavros Therapeutics is a precision oncology platform company leading the new frontier of targeted therapies exploiting tumors’ genetic vulnerabilities. The result is a drug discovery engine that can discover novel drug targets with a clear path forward to the clinic to get the right drugs to the right patients, faster.
Velocity Clinical Research is an Owned Clinical Site Business comprised of 30 fully-integrated, centrally controlled research sites. Our model delivers superior accelerated enrollment and consistent, reliable results – helping our clients maintain the highest standards of care while bringing disruptive, innovative medical treatments to patients as quickly and efficiently as possible. We are driving improvement of the clinical research industry by advancing site-level productivity by further developing efficiencies that can only be achieved in an owned site model, ultimately leading to improved study execution.
